Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction a one-year prospective study.docVIP

Available online /content/8/1/R3 Research article Open Access Vol 8 No 1 Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study Fabiola Atzeni1, Piercarlo Sarzi-Puttini1, Donata Dell Acqua1, Simona de Portu2, Germana Cecchini3, Carola Cruini3, Mario Carrabba1 and Pier Luigi Meroni3 1Rheumatology Unit, Department of Medicine, L Sacco University Hospital, 74 Via GB Grassi, 20157 Milano, Italy 2CIRF/Center of Pharmacoeconomics, Faculty of Pharmacy, University of Naples, Federico II, Napoli